CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news